Protalix (PLX) Director Aharon Schwartz Receives RSU Awards

What Happened Aharon Schwartz, a director of Protalix BioTherapeutics (PLX), received two awards on September 3, 2026 totaling 25,500 derivative awards: 17,000 and 8,500 units. Each unit is reported at $0.00 (no cash exchanged) and represents a right to receive one share of common stock upon vesting. These awards are grants (not open‑market purchases or sales).

Key Details

• Transaction date: 2026-09-03; Form 4 filed: 2026-09-09 (filed 6 days after the grant; outside the standard 2-business-day Form 4 window).
• Awards: 17,000 and 8,500 RSUs (total 25,500); reported price: $0.00; reported value: $0 at grant per filing format.
• Vesting: The RSUs vest in 12 equal quarterly installments commencing on the grant date (i.e., quarterly over ~3 years) — each RSU converts to one common share upon vesting (Footnotes F3, F4).
• Shares owned after transaction: Not specified in the provided filing summary.
• Other outstanding options: Filing notes several separate option grants not part of this award (40,000 @ $3.55 exp 1/20/2030; 50,000 @ $1.03 exp 9/7/2032; 61,676 @ $1.66 exp 9/29/2033; 15,000 @ $1.64 exp 9/3/2035) (Footnote F2).
• Filing remark: Exhibit 24.1 (Power of Attorney) included.

Context These are restricted stock units (RSUs) — a grant of future shares that vests over time — not an immediate purchase or sale. Because no shares were delivered at grant and the awards vest quarterly, the transaction does not reflect an immediate change in public float or a stock sale. The late filing means the public saw the award after it was granted; late filings are administrative issues but can delay transparency for investors.